Menu
Investing into the manufacture of next generation psychedelic neuromedicines for key mental illnesses; and to supply psychedelic medicines for trials and compassionate access schemes globally.
Aims to improve manufacturing, distribution and global access to psychotropic medicines to combat, common illnesses including (but not limited to): Depression, Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), Obsessive Compulsive Disorder (OCD), Body Image and Substance Use Disorders (SUDs)
Target Year 1: To distribute 10kg of MDMA to pharmaceutical groups for R&D in Eu & UK.
Apply for pharmaceutical psychotropic license
Timing: 6-9 months
Update:
Mynd Pharmaceuticals company now registered
Acquire an existing building in the Algave of Portugal
Timing: Already located & identified as suitable
Update:
Contract manufacturer secured in Portugal
Repurpose the facility into an EUGMP – API certified facility & engage modular building company to design & build fitout.
Timing: 3 months
Ordering of pharmaceutical plant & equipment to manufacture.
Timing: 3-6 months
Appoint sales team to liaise with pharmarceutical companies to obtain LOI’s during the build stage.
Commence manufacturing & distribution
Timing: 6 months post issue of license
56 STEEL STREET NORTH MELBOURNE VICTORIA AUSTRALIA 3051
56 STEEL STREET NORTH MELBOURNE VICTORIA AUSTRALIA 3051
chris@myndbiotech.com
bruce@myndbiotech.com